150,000 patients tracked: does finerenone protect hearts in kidney disease and diabetes?

NCT ID NCT06608212

Ongoing Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This observational study follows 150,000 people with chronic kidney disease and type 2 diabetes to see how finerenone (Kerendia) works in everyday medical care. Researchers will compare those taking finerenone to those not taking it, looking at rates of heart attacks and heart failure hospitalizations. No extra visits or tests are required—only existing health records are used.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: finerenone (Kerendia)
What this could lead to: If successful, this study could confirm that finerenone is safe and effective for preventing heart attacks and heart failure hospitalizations in real-world patients with CKD and T2D.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It only looks at existing data, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Bayer

Whippany, New Jersey, 07981, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.